US proposes more stringent conflict-of-interest rules

Kondro, Wayne
May 2007
CMAJ: Canadian Medical Association Journal;5/22/2007, Vol. 176 Issue 11, p1571
Academic Journal
The article reports on the conflict-of-interest rules proposed by the U.S. Food and Drug Administration (FDA) that address medical professionals that hold financial interests in pharmaceutical companies. It states that the rules will prevent medical personnel having $50,000 financial interest to take part in reviewing the company's product. It was shown that only those physicians with below $50,000 will be allowed to participate.


Related Articles

  • Financial Conflicts of Interest and the Food and Drug Administration's Advisory Committees. Steinbrook, Robert // New England Journal of Medicine;7/14/2005, Vol. 353 Issue 2, p116 

    Focuses on the U.S. Food and Drug Administration, in light of a February meeting that discussed the safety of cyclooxygenase-2 (COX-2) inhibitors. The FDA stance on conflict of interest on the part of advisory committee members; Data indicating panel members had financial associations with...

  • Proposed FDA Conflict-of-Interest Guidelines Get Lukewarm Reception. Finkeistein, Joel B. // JNCI: Journal of the National Cancer Institute;5/16/2007, Vol. 99 Issue 10, p747 

    The article reports that the U.S. Food and Drug Administration (FDA) has shed light on the process of vetting advisory committee members. It mentioned that the FDA has come under the increasing pressure from the U.S. Congress to implement stricter supervision of regulated products. From the...

  • WATCHDOGS POODLES, GUINEA PIGS AND DRUGS.  // Ecologist;Dec2006, Vol. 36 Issue 10, p12 

    This article explains that when it comes to a conflict of interest, it is hard to beat that which exists between the global pharmaceutical corporations and the U.S. drug watchdog. Regulators usually do not negotiate their budgets with the industries they oversee… but the U.S. Food and Drug...

  • FDA Seeks Stricter Guidelines For Advisory Approval Panels.  // Quality Progress;May2007, Vol. 40 Issue 5, p12 

    The article reports on the proposal of the U.S. Food and Drug Administration (FDA) to create guidelines that will reduce conflicts of interest among people who approve drugs and medical devices. The new rules will disqualify physicians and scientific researchers from serving on FDA advisory...

  • Conflict of interest and resignation at drug agency.  // Nature;8/20/2009, Vol. 460 Issue 7258, p943 

    The article focuses on the problems that occurred in the U.S. Food and Drug Administration (FDA). FDA's medical device division head Daniel Schultz resigned due to allegations from employees on approved products despite the concerns of agency scientists. Also, California-based Amphastar...

  • FDA is criticised for hinting at looser conflict of interest rules. Lenzer, Jeanne // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/13/2011, Vol. 343 Issue 7819, p338 

    No abstract available.

  • Ethics group wants FDA to drop two tobacco panel advisers over 'conflicts'. Pecquet, Julian // Hill;6/8/2010, Vol. 17 Issue 63, p18 

    The article reports that good-government group Citizens for Responsibility and Ethics in Washington is urging the U.S. Food and Drug Administration to dismiss two members of its advisory panel on tobacco products for financial conflicts of interests.

  • Conflicts of Interest Among Patient and Consumer Representatives to U.S. Food and Drug Administration Drug Advisory Committees. Graham, S. Scott; Card, Daniel J.; Seokhoon Ahn; Sang-Yeon Kim; Kessler, Molly M.; Olson, Michelle K.; Ahn, Seokhoon; Kim, Sang-Yeon // Annals of Internal Medicine;10/18/2016, Vol. 165 Issue 8, p606 

    A letter to the editor is presented in response to the article "Measuring conflict of interest and expertise on FDA advisory committees" by N. Ackerly in the December 10, 2013 issue.

  • Solving Conflict of Interest. Agres, Ted // Drug Discovery & Development;Jun2007, Vol. 10 Issue 6, p14 

    The article discusses the new rules implemented by the U.S. Food and Drug Administration (FDA). FDA has fastened their rules that cover the individuals with financial conflicts of interest. The new rules will hinder the research and consulting firms from serving in scientific and other advisory...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics